CD86 and cervical cancer: The present data suggest that high expression of SIGLEC9 is positively correlated with immune checkpoint genes such as LAG3, HAVCR2, CD86, and PD-1, implying that SIGLEC9 may contribute to the suppression of anti-tumor immune responses in cervical cancer by regulating these immune checkpoint molecules.